Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. It engages in the business of developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company was founded by Axel Bolte, Joseph P. Schlessinger, and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.
相关临床试验
19
7 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2016
进行中（未招募）
7
36.8%
已完成
7
36.8%
招募中
4
21.1%
撤回
1
5.3%
暂无批准数据
- BioMarin Pharmaceutical will acquire privately held Alesta Therapeutics for $275 million up front, with up to $215 million more in development and regulatory milestones. - Alesta's lead candidate ALE1 is in a Phase 1/2 trial for hypophosphatasia, a genetic disease affecting bone mineralization that can cause fractures, tooth loss, and muscle weakness. - ALE1 acts on a novel target that lowers inorganic pyrophosphate, a metabolite central to hypophosphatasia, and could reach BioMarin's largest addressable patient population. - The deal, BioMarin's third acquisition in two years, is expected to close by the end of September and will be funded with cash on hand.
- GlycoEra AG has appointed Petra Duda, M.D., Ph.D., as Chief Medical Officer to lead clinical development of its precision immune degrader pipeline. - Dr. Duda brings over 20 years of experience in clinical development and regulatory strategy, with expertise in immune-mediated and rare diseases. - She will oversee advancement of GlycoEra's lead IgG4 degrader program GE8820 for autoimmune diseases including pemphigus, MuSK MG, and primary membranous nephropathy. - The appointment comes as GlycoEra advances its glyco-engineering platform designed to degrade disease-causing proteins without generalized immunosuppression.
- BioMarin completed its $270 million acquisition of Inozyme Pharma in July 2025, paying $4.00 per share to gain access to the enzyme replacement therapy INZ-701. - The experimental therapy targets ENPP1 Deficiency, a rare genetic disorder causing dangerous blood vessel and bone calcification, with early data showing 80% infant survival versus 50% historical rates. - Critical Phase 3 ENERGY-3 trial results are expected in early 2026, which could lead to regulatory submission and potential market approval by 2027. - INZ-701 has received FDA Fast Track designation for ABCC6 Deficiency and demonstrated favorable safety profiles with improved biomarkers in earlier studies.
- BioMarin Pharmaceutical has entered into a definitive agreement to acquire Inozyme Pharma for $270 million, strengthening its enzyme therapy portfolio with the addition of INZ-701. - INZ-701 is a Phase 3 enzyme replacement therapy being developed for ENPP1 Deficiency, a rare genetic condition affecting blood vessels, soft tissues, and bones with no currently approved treatments. - The first pivotal data readout for INZ-701 in children is expected in early 2026, with potential regulatory approval and market launch in 2027.
- Interim data from Inozyme Pharma's ENERGY 3 pivotal trial demonstrates INZ-701's potential to modify disease course in pediatric ENPP1 Deficiency patients, with sustained phosphate increases and favorable safety profile. - The trial is progressing well with no patient dropouts, dose adjustments, or discontinuations, and remains on track for topline data in Q1 2026, positioning INZ-701 to potentially become the first approved therapy for this rare disease. - Inozyme has appointed Petra Duda, M.D., Ph.D. as Chief Medical Officer, bringing over two decades of expertise in rare disease clinical development as the company advances toward late-stage development milestones.
- Pharmaceutical M&A activity is experiencing a significant rebound with major deals including Novartis's $1.7 billion acquisition of Regulus Therapeutics and Merck KGaA's $3.9 billion purchase of SpringWorks Therapeutics. - Small-cap biotechs are becoming prime acquisition targets as 22% of the sector now trades below cash value, the highest level in nine years, creating opportunities for pharma companies with strong balance sheets. - Major pharmaceutical companies including Pfizer, Bristol Myers Squibb, and Sanofi have signaled business development as a top priority, with Pfizer specifically targeting $10-15 billion acquisitions to rebuild its pipeline. - Deal momentum in biotech and pharma sectors rose 63% in Q1 2025 after falling 26% over the previous 12 months, indicating a market recovery despite ongoing tariff concerns.
- The FDA's rare pediatric disease Priority Review Voucher program expired in December 2023, despite unanimous congressional support for renewal, leaving biotech companies unable to receive new vouchers worth approximately $150 million. - Eleven priority review vouchers were awarded in 2023, marking a record year, with beneficiaries including treatments for sickle cell disease, Duchenne muscular dystrophy, and other rare conditions. - The program's suspension threatens future rare disease drug development, as many companies rely on voucher sales for funding, with existing designations only valid until September 2026 for voucher eligibility.
• Inozyme Pharma's INZ-701 demonstrated improved survival rates in infants with ENPP1 Deficiency, with 80% surviving beyond one year compared to a historical 50%. • The ENERGY 3 pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency has completed enrollment, with topline data expected in early 2026. • Preliminary regulatory support has been received for the ASPIRE pivotal trial of INZ-701 in children with ABCC6 Deficiency, targeting major adverse clinical events. • INZ-701 was well-tolerated in trials, showing substantial reductions or stabilization of arterial calcifications and improvements in heart function in treated patients.
